Research conducted by professors at the University of Glasgow, show the role played by a gene involved in the development of lymphoma. The results of these tests may lead to increased effectiveness of treatment of a number of cancers.
RUNX1 gene supports the establishment of healthy blood cells by controlling the activity level of other genes. When he becomes a "hyperactive", that is a key factor in the uncontrolled growth of cancer cells in many types of cancer.
Scientists have found that certain types of cancer who have not previously been associated with changes affecting RUNX1, depend on the gene, even when it is working properly. The results showed that the "off» RUNX1 gene makes lymphoma cells more sensitive to chemotherapy.
A team led by Professor James Neil and Evan Cameron studied mice with Burkitt's type, associated with mutations in the MYC gene. When RUNX1 gene was deleted, the growth of tumor significantly decreased, and the cancer cells are more sensitive to chemotherapy.
Researchers are now working with US scientists who have developed a drug that blocks the gene RUNX1. "There is damage to many genes or mutations, when healthy cells are transformed into cancer. This leads to uncontrolled growth of cancer. Understanding that faulty genes are able to interact with each other in order to change the behavior of the cell, has helped scientists find the "Achilles' heel" of cancer. Lock RUNX1 gene provides an indirect effect on the ability of other genes cooperate to further develop lymphoma ", said Professor of Molecular and Cellular Oncology James Neil.
Based on materials medicalnewstoday.com